Observational studyIndian journal of ophthalmology2026
Successful use of intravitreal rituximab as salvage therapy for relapsed vitreoretinal lymphoma.
Observational study in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the outcomes, response patterns, and complications of intravitreal rituximab (IVR) in eyes with relapsed vitreoretinal lymphoma (VRL) despite previous treatment with ocular radiotherapy (EBRT).
methodsRetrospective observational single-center study. This study included all patients diagnosed with relapsed VRL who received IVR between 2011 and 2024 at our National Ocular Oncology Service in the United Kingdom. Demographic data, systemic and ocular lymphoma history, treatment details, visual acuity, and ocular adverse events were collected from medical records.
resultsTen eyes of six patients with relapsed VRL were treated with IVR. All eyes had been previously treated with ocular EBRT and with whole brain radiotherapy (WBRT) (83.3%) and systemic chemotherapy (66.7%) for CNS lymphoma. Eyes with relapsed VRL were treated with a mean of four IVR injections (1 mg/0.1 mL) per treatment course using weekly to monthly intervals. Complete ocular remission was achieved in all eyes after a single course of IVR. One eye experienced a further relapse 14 months later, successfully treated with a second course of IVR. Ocular adverse events potentially attributable to IVR included transient intraocular hypertension and mild uveitis; other complications, such as cataract, radiation retinopathy, and retinal atrophy were likely related to EBRT rather than IVR.
conclusionIn our cohort of relapsed VRL despite previous ocular EBRT, IVR used as a sole focal therapy was associated with high rates of ocular remission and acceptable local toxicity. These findings support the use of IVR as a standard salvage treatment in cases of relapsed VRL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.